探索Ephx2在治疗动脉样硬化的机制,使用独立级联模型和不良结果途径
Caiyuzhen Zhang1, Yuanwen Dai1, Yong Chen1
1Jiangxi Normal University, 100875, China.
Combinatorial chemistry & high throughput screening
|March 28, 2025
概括
这项研究揭示了酶Ephx2 (可溶性环氧化酶) 如何通过识别关键途径和目标基因 (如Mapk3.3) 来影响动脉样硬化 (AS). 这些发现为AS治疗提供了新的治疗点.
科学领域:
- 心血管生物学 心血管生物学
- 疾病的分子机制.
- 药物基因组学 药物基因组学
背景情况:
- 动脉样硬化 (AS) 涉及动脉脂质的积累,是主要的心血管疾病风险.
- 酶Ephx2 (可溶性环氧化酶,sEH) 在AS中起作用,但其确切的功能和治疗相关性需要进一步研究.
研究的目的:
- 分析LDLR淘汰赛小鼠的基因表达,有或没有Ephx2,以找到与AS相关的基因.
- 构建基因-蛋白质相互作用网络并使用计算模型来理解Ephx2在AS病变发生中的作用.
主要方法:
- 从LDLR淘汰和LDLR/sEH双淘汰小鼠的基因表达数据分析.
- 使用KEGG通路构建一个化合物-蛋白相互作用网络.
- 应用独立级联 (IC) 模型和阻力距离 (RD) 来识别不良结果途径 (AOP) 和关键基因.
主要成果:
- 通过Ephx2识别AS治疗中的关键AOP,包括炎症,胆固醇代谢,斑块稳定性,光滑肌肉细胞活性和凝血.
- 在炎症反应途径中发现了潜在的目标基因,如Mapk3,PiK3cd,Gnai2,Mapk10,Arnt和RhoA.
- 揭示了连接Ephx2与这些目标基因的关键通路,这表明它对AS发展的影响.
结论:
- 该研究定义了一个AS网络,透露了通过KEGG通路,AOP和目标基因的Ephx2的机制.
- 增强对AS病原学的理解,并确定Mapk3作为AS预防和治疗的潜在治疗点.
相关概念视频
01:30Coronary Artery Disease I: Introduction
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
01:26Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
01:30Atherosclerosis I: Introduction
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
01:27Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...